|
1
|
Godley P and Kim SW: Renal cell carcinoma.
Curr Opin Oncol. 14:280–285. 2002. View Article : Google Scholar
|
|
2
|
Fishman M and Seigne J: Immunotherapy of
metastatic renal cell cancer. Cancer Control. 9:293–304.
2002.PubMed/NCBI
|
|
3
|
Vicari AP and Caux C: Chemokines in
cancer. Cytokine Growth Factor Rev. 13:143–154. 2002. View Article : Google Scholar
|
|
4
|
Navarini-Meury AA and Conrad CC: Melanoma
and innate immunity-active inflammation or just erroneous
attraction? Melanoma as the source of leukocyte-attracting
chemokines. Semin Cancer Biol. 19:84–91. 2009.
|
|
5
|
Skommer J, Wlodkowic D and Pelkonen J:
CXCR4 expression during tumour cell death. Leuk Res. 31:1155–1156.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Burger JA and Kipps TJ: CXCR4: a key
receptor in the crosstalk between tumor cells and their
microenvironment. Blood. 107:1761–1767. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Broxmeyer HE, Orschell CM and Clapp DW:
Rapid mobilization of murine and human hematopoietic stem and
progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med.
201:1293–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Labrosse B, Brelot A and Heveker N:
Determinants for sensitivity of human immunodeficiency virus
coreceptor CXCR4 to the bicyclam AMD3100. J Virol. 72:6381–6388.
1998.PubMed/NCBI
|
|
9
|
Hendrix CW, Collier AC, Lederman MM, et
al: Safety, pharmacokinetics, and antiviral activity of AMD3100, a
selective CXCR4 receptor inhibitor, in HIV-1 infection. J Acquir
Immune Defic Syndr. 37:1253–1262. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Paul S, Mancuso P, Rabascio C, et al: In
Vitro and Preclinical Activity of the Novel AMD3100 CXCR4
Antagonist in Lymphoma Models. In: American Society of Hematology
Annual Meeting; 2002; Philadelphia, PA, USA. Blood. 2002
|
|
11
|
Duxbury MS and Whang EE: RNA interference:
a practical approach. J Surg Res. 117:339–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Wang Z, Yang B, et al: CXCR4
nuclear localization follows binding of its ligand SDF-1 and occurs
in metastatic but not primary renal cell carcinoma. Oncol Rep.
22:1333–1339. 2009.PubMed/NCBI
|
|
13
|
Zlotnik A and Yoshie O: Chemokines: a new
classification system and their role in immunity. Immunity.
12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zlotnik A: Chemokines and cancer. Int J
Cancer. 119:2026–2029. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim J, Takeuchi H, Lam ST, et al:
Chemokine receptor CXCR4 expression in colorectal cancer patients
increases the risk for recurrence and for poor survival. J Clin
Oncol. 23:2744–2753. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiller DJ, Li BD and Chu QD: CXCR4 as a
predictive marker for locally advanced breast cancer
post-neoadjuvant therapy. J Surg Res. 166:14–18. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xie L, Wei J, Qian X, et al: CXCR4, a
potential predictive marker for docetaxel sensitivity in gastric
cancer. Anticancer Res. 30:2209–2216. 2010.PubMed/NCBI
|
|
18
|
Spoo AC, Lubbert M and Wierda WG: CXCR4 is
a prognostic marker in acute myelogenous leukemia. Blood.
109:786–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Laverdiere C, Hoang BH and Yang R:
Messenger RNA expression levels of CXCR4 correlate with metastatic
behavior and outcome in patients with osteosarcoma. Clin Cancer
Res. 11:2561–2567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun YX, Wang J, Shelburne CE, et al:
Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers
(PCa) in vivo. J Cell Biochem. 89:462–473. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zagzag D, Krishnamachary B, Yee H, et al:
Stromal cell-derived factor-1alpha and CXCR4 expression in
hemangioblastoma and clear cell-renal cell carcinoma: von
Hippel-Lindau loss-of-function induces expression of a ligand and
its receptor. Cancer Res. 65:6178–6188. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Thomas CW, Claudine G, Stefan B, et al:
Strong expression of chemokine receptor CXCR4 by renal cell
carcinoma correlates with advanced disease. J Oncol. 2008:1–6.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang LH, Liu Q, Xu B, et al:
Identification of nuclear localization sequence of CXCR4 in renal
cell carcinoma by constructing expression plasmids of different
deletants. Plasmid. 63:68–72. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin SY, Makino K, Xia W, et al: Nuclear
localization of EGF receptor and its potential new role as a
transcription factor. Nat Cell Biol. 3:802–808. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sherr CJ: Cancer cell cycles. Science.
274:1672–1677. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khan MZ, Shimizu S, Patel JP, et al:
Regulation of neuronal P53 activity by CXCR 4. Mol Cell Neurosci.
30:58–66. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gerlach LO, Skerlj RT, Bridger GJ, et al:
Molecular interactions of cyclam and bicyclam non-peptide
antagonists with the CXCR4 chemokine receptor. J Biol Chem.
276:14153–14160. 2001.PubMed/NCBI
|
|
28
|
Dewan MZ, Ahmed S, Iwasaki Y, et al:
Stromal cell-derived factor-1 and CXCR4 receptor interaction in
tumor growth and metastasis of breast cancer. Biomed Pharmacother.
60:273–276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burger M, Glodek A, Hartmann T, et al:
Functional expression of CXCR4 (CD184) on small-cell lung cancer
cells mediates migration, integrin activation, and adhesion to
stromal cells. Oncogene. 22:8093–8101. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hartmann TN, Burger JA, Glodek A, et al:
CXCR4 chemokine receptor and integrin signaling co-operate in
mediating adhesion and chemoresistance in small cell lung cancer
(SCLC) cells. Oncogene. 24:4462–4471. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chao DT and Korsmeyer SJ: Bcl-2 family:
regulators of cell death. Annu Rev Immunol. 16:395–419. 1998.
View Article : Google Scholar
|
|
32
|
Carmen HL, Jaris V, Laura Hi, et al:
CXCL12/CXCR4 signaling promotes human thymic dendritic cell
survival regulating the Bcl-2/Bax ratio. Immunol Lett. 120:72–78.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zheng H, Dai T, Zhou B, et al:
SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis
under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis.
201:36–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao F, Gao E, Yue TL, et al: Nitric oxide
mediates the antiapoptotic effect of insulin in myocardial
ischemia-reperfusion: the roles of PI3-kinase, Akt, and endothelial
nitric oxide synthase phosphorylation. Circulation. 105:1497–1502.
2002. View Article : Google Scholar
|
|
35
|
Yin G, Li LY, Qu M, Luo HB, Wang JZ and
Zhou XW: Upregulation of AKT attenuates amyloid-β-induced cell
apoptosis. J Alzheimers Dis. 25:337–345. 2011.
|
|
36
|
New DC, Wu K, Kwok AW, et al: G
protein-coupled receptor-induced Akt activity in cellular
proliferation and apoptosis. FEBS J. 274:6025–6036. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ljungberg B, Cowan NC, Hanbury DC, et al:
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol.
58:401–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
